300.93MMarket Cap-5446P/E (TTM)
7.410High7.190Low34.94KVolume7.380Open7.240Pre Close254.60KTurnover0.10%Turnover RatioLossP/E (Static)41.85MShares8.44052wk High6.17P/B259.39MFloat Cap3.89052wk Low--Dividend TTM36.08MShs Float418.400Historical High--Div YieldTTM3.04%Amplitude2.560Historical Low7.286Avg Price1Lot Size
Zevra Therapeutics Stock Forum
$Humacyte (HUMA.US)$ : 🤔
⇨ Human Acellular Vessel (HAV)™
‣ Vascular Trauma
‣ PDUFA: 8/10/24 (BLA)
🗓️ Last Week’s AdCom & PDUFAs:
$Zevra Therapeutics (ZVRA.US)$ : Favorable AdCom 👍
🗳️ 11-5 votes in favor
⇨ Arimoclomol
‣ Niemann-Pick disease type C
‣ AdCom: 8/2/24 (NDA)
$Adaptimmune Therapeutics (ADAP.US)$ : Approved 🎉
⇨ TECELRA (afamitresgene autoleucel)
‣ Synovial sarcoma
‣ PDUFA: 8/4/24 (BLA)
$GlaxoSmithKline (GSK.US)$ : Approved 🎉
⇨ Jemperli
‣ Endometria...
📊⚡️📊
FDA Advisory Committee Votes Favorably that the Data Support Arimoclomol as Effective Treatment for Patients with Niemann-Pick Disease Type C
Zevra Therapeutics said a Food and Drug Administration advisory committee voted favorably on Arimoclomol as a treatment for patients with Niemann-Pick Disease Type C.
The FDA Genetic Metabolic Diseases Advisory Committee voted 11-5 that data support Arimoclomol as effective in the treatment of patients with the rare progre...
Zevra Therapeutics Inc: Arimoclomol Nda Has Been Assigned a Prescription Drug User Fee Act Action Date of Sept 21, 2024
No comment yet